@article{c28a67cc5a894bb5aa9b045edc1eacf0,
title = "Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States",
abstract = "Objective: Although a high-resolution computed tomography (HRCT) scan of the chest is the gold standard test for the detection of interstitial lung disease (ILD), there is no consensus among rheumatologists regarding the use of HRCT to screen for ILD in their patients with systemic sclerosis (SSc). The aims of this study were to describe the HRCT ordering practices at SSc centers in the United States and to determine which patient characteristics are associated with HRCT performance. Methods: We performed a prospective cohort study of patients with SSc enrolled in the US-based Collaborative National Quality and Efficacy Registry (CONQUER). We performed univariate logistic regression followed by multivariable logistic regression to determine which patient characteristics were associated with HRCT performance. Results: Of the 356 patients with SSc enrolled in CONQUER, 286 (80.3%) underwent HRCT at some point during their disease course. On multivariable analyses, missing total lung capacity percent predicted (odds ratio [OR] 3.26, 95% confidence interval [CI]: 1.53-7.41, P = 0.007) was positively associated with ever having undergone HRCT, whereas a positive anti-centromere antibody (OR 0.27, 95% CI: 0.12-0.61, P = 0.008) and missing forced vital capacity percent predicted (OR 0.29, 95% CI: 0.10-0.80, P = 0.005) were negatively associated with ever having undergone HRCT. There was a trend toward a positive association between crackles on pulmonary exam and ever having undergone HRCT (OR 2.28, 95% CI: 0.97-6.05, P = 0.058), although this relationship did not reach statistical significance. Conclusion: The majority of patients with SSc enrolled in CONQUER underwent HRCT. A positive anti-centromere antibody was the key clinical variable inversely associated with performance of HRCT.",
author = "Bernstein, {Elana J.} and Shervin Assassi and Castelino, {Flavia V.} and Lorinda Chung and Chase Correia and Evnin, {Luke B.} and Frech, {Tracy M.} and Gordon, {Jessica K.} and Skaug, {Brian A.} and Hant, {Faye N.} and Hummers, {Laura K.} and Nora Sandorfi and Shah, {Ami A.} and Shanmugam, {Victoria K.} and Steen, {Virginia D.} and Dinesh Khanna",
note = "Funding Information: Dr. Bernstein's work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grant K23-AR-075112). Dr. Assassi's work was supported by the US Department of Defense (grant W81XWH-16-1-0296) and NIH/NIAMS (grant R01-AR-073284). Dr. Frech's work was supported by NIH/NIAMS (grant K23-AR-067889). Dr. Shah's work was supported by NIH/NIAMS (grant R01-AR-073208). Dr. Khanna's work was supported by NIH/NIAMS (grants K24-AR-063120 and R01-AR-070470). The Collaborative National Quality and Efficacy Registry (CONQUER) is supported by the Scleroderma Research Foundation (SRF), and the SRF has received financial support for CONQUER from the founding sponsors, Boehringer Ingelheim and Actelion Pharmaceuticals US, Inc (a Janssen Pharmaceutical Company of J&J). Dr. Assassi receives consulting fees from Boehringer Ingelheim, Novartis, Abbvie, and Corbus. Dr. Castelino has received consulting fees from Boehringer Ingelheim. Dr. Chung has received consulting fees from Boehringer Ingelheim, Genentech, Mitsubishi Tanabe, and Eicos Sciences and served on the Data Safety Monitoring Board for Reata. Dr. Evnin is Chairman of the Board of the Scleroderma Research Foundation (a volunteer, uncompensated position) and is co-founder and co-owner of MPM Capital, a venture capital firm that has invested in various biopharmaceutical companies. Dr. Evnin currently represents MPM Capital on the Board of Directors for each of Blade Therapeutics, Trishula Therapeutics, Oncorus, Frontier Medicines, Werewolf Therapeutics, TwentyEight-Seven Therapeutics, and Umoja Biopharma. Dr. Evnin owns stock directly in Eicos Sciences, an affiliate of CiVi Biopharma. Dr. Gordon has received research funding from Eicos Sciences and Cumberland Pharmaceuticals. Dr. Hummers has received consulting fees from Boehringer Ingelheim, Corbus Pharmaceuticals, CSL Behring, and Abbvie. Dr. Steen has received consulting fees from Boehringer Ingelheim, Corbus, CSL Behring, and Eicos and was an independent medical monitor for Galapagos. Dr. Khanna reports personal fees from Acceleron, Actelion, Amgen, Bayer, Blade Therapeutics, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/Roche, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics. Dr. Khanna is Chief Medical Officer of Eicos Sciences, Inc, a subsidiary of CiviBioPharma, and has stock options. No other disclosures relevant to this article were reported. Publisher Copyright: {\textcopyright} 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.",
year = "2022",
month = jul,
doi = "10.1002/acr2.11434",
language = "English (US)",
volume = "4",
pages = "596--602",
journal = "ACR Open Rheumatology",
issn = "2578-5745",
publisher = "John Wiley and Sons Inc.",
number = "7",
}